Immunotherapy in advanced esophageal squamous cell cancer: earlier or later?

Shuang Wei, Zuoji Li, Tingting Liu, Guizhen Sun, Hongfu Sun, Wei HuangResearch Square 2024 · DOI

Abstract

Background and Objective: Large-scale phase III clinical trials have established immunotherapy as a standard of care for advanced esophageal squamous cell cancer (ESCC). However, the optimal timing—whether to use it in the first-line or second-line setting—remains debated. This study investigates whether early immunotherapy (EIT) improves long-term survival compared to late immunotherapy (LIT).

Methods: This retrospective study analyzed 359 patients with locally advanced or metastatic ESCC. Patients were divided into EIT (first-line) and LIT (second-line) groups. Propensity score matching (PSM) was used to balance baseline characteristics.

Results: After matching, 107 patients remained in each group. While EIT significantly improved progression-free survival (PFS1: 8.7 vs. 7.6 months, $P=0.032$; PFS2: 12.97 vs. 12.93 months, $P=0.045$), it did not significantly improve overall survival (OS: 15.7 vs. 17.7 months, $P=0.185$). Multivariate analysis identified EIT and tumor differentiation as independent predictors of OS.

Conclusions: For advanced ESCC, early immunotherapy improves progression-free survival but does not translate into a significant overall survival benefit compared to sequential use.

Introduction

Esophageal squamous cell cancer (ESCC) is a highly aggressive malignancy, particularly prevalent in China. While immunotherapy has revolutionized treatment, clinicians face a strategic dilemma: should these agents be deployed immediately in the first-line setting (Early Immunotherapy, EIT), or reserved for when initial chemotherapy fails (Late Immunotherapy, LIT)? Theoretically, early intervention might prevent tumor complexity, but real-world data on the long-term survival benefits of this "earlier is better" approach versus a sequential strategy are limited.

Methods

The researchers conducted a retrospective analysis of 359 patients treated at Shandong Cancer Hospital between 2018 and 2021. To ensure a fair comparison, the study utilized Propensity Score Matching (PSM) at a 1:1 ratio to balance baseline characteristics such as age, sex, and tumor location.

Table 1: Baseline clinical characteristics of the EIT and LIT groups before and after propensity score matching (PSM).

Patients were categorized into:

  • EIT Group: Received immunotherapy as part of first-line treatment.
  • LIT Group: Received standard chemotherapy first, followed by immunotherapy as second-line treatment.

Key Results

Survival Outcomes

The study revealed a disconnect between progression-free survival and overall survival:

  • Progression-Free Survival (PFS): EIT showed a clear advantage. PFS1 was 8.7 months for EIT vs. 7.6 months for LIT ($P=0.032$). PFS2 also favored EIT at 12.97 months vs. 12.93 months ($P=0.045$).
  • Overall Survival (OS): There was no statistically significant difference. The EIT group had a median OS of 15.7 months compared to 17.7 months in the LIT group ($P=0.185$).

Multivariate Analysis

Despite the lack of OS difference in the matched cohort, COX multivariate analysis indicated that the treatment group (EIT vs. LIT) and the degree of tumor differentiation were significant independent factors affecting overall survival.

Table 3: Multivariate COX analysis identifying independent predictors of overall survival.

Key Insights and Discussion

  • The "Catch-up" Effect: The lack of OS benefit in the EIT group may be attributed to subsequent treatment opportunities. Approximately 30% of the LIT group received third-line therapy, compared to only 15.5% of the EIT group, potentially equalizing survival outcomes.
  • Subgroup Benefits: Early immunotherapy appeared more beneficial for specific subgroups: males, patients under 65, those with middle thoracic tumors, and those receiving a paclitaxel plus platinum (TP) chemotherapy backbone.
  • Safety Profile: Treatment-related adverse events (TRAEs) were similar across both groups, with roughly 60% of patients experiencing Grade 3 or higher side effects, suggesting that early use does not significantly increase the toxicity burden.

Limitations and Future Work

As a retrospective study, these findings are subject to inherent biases. The lack of PD-L1 expression data—a critical biomarker for immunotherapy response—limits the ability to assess if biological profiles influenced the outcomes. Future prospective, randomized trials incorporating PD-L1 status are necessary to definitively determine the optimal timing for immunotherapy in ESCC.

Summary updated

Abstract

<title>Abstract</title> Background and objective: Several large-scale phase III clinical trials have confirmed the survival benefit of immunotherapy in patients with locally advanced or metastatic esophageal cancer. The aim of this study is to investigate whether early use of immunotherapy can improve long-term survival. Methods: Patients with locally advanced or metastatic esophageal squamous cell cancer (ESCC) diagnosed from January 2018 to December 2021were retrospectively analyzed. According to the time of immunotherapy, patients were divided into early immunotherapy group (EIT group, first-line immunotherapy ) and late immunotherapy group (LIT group, second-line immunotherapy) . A 1:1 propensity score matching (PSM) was applied to balance the observable potential confounding factors between the two groups. The primary outcome was overall survival (OS). Results: A total of 359 patients were enrolled, after propensity score matching, the clinical features were well balanced between two groups included 107 patients each. The median OS was 15.7 months (95%CI: 12.81-18.59) in the EIT group and 17.7 months (95%CI: 14.89-20.57) in the LIT group, respectively. (<italic>P</italic>=0.185, HR=1.25). The PFS1 of patients were 8.7 months (95%CI: 7.53-9.87) and 7.6 months (95%CI: 5.90-9.30),respectively, and the difference was statistically significant (<italic>P</italic>=0.032, HR=0.72). The PFS2 of patients were 12.97months (95%CI: 11.37-14.58) and 12.93 months (95%CI: 11.65-14.21), respectively, and the difference was statistically significant(<italic>P</italic>=0.045,HR=0.73). Subgroup analysis showed that male patients with middle thoracic esophageal cancer, younger than 65 years old, only one site of metastasis, only lymph node progression, no combined radiotherapy after progression and TP (paclitaxel plus platinum) regimen chemotherapy may have greater benefits. COX multivariate analysis showed that the EIT group and the differentiation degree of tumor had an impact on overall survival (<italic>P:</italic>0.03、0.04, HR: 0.73、0.70). Conclusions: For patients with locally advanced or metastatic advanced ESCC, earlyimmunotherapy can improve PFS without improving OS.
BibTeX
@inproceedings{wei2024immunotherapy,
  author = {Shuang Wei and Zuoji Li and Tingting Liu and Guizhen Sun and Hongfu Sun and Wei Huang},
  title = {{Immunotherapy in advanced esophageal squamous cell cancer: earlier or later?}},
  booktitle = {Research Square},
  year = {2024},
  doi = {10.21203/rs.3.rs-4571189/v1},
}
Figure